Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553637 | 0.91 | WEE1 (0.54) | WEE1JAK3FGFR1PDGFRBSRC | |
| SCHEMBL15787829 | 0.77 | PKN1 (0.56) | WEE1JAK3FGFR1PDGFRBSRC | |
| SCHEMBL15036006 | 0.76 | TNK2 (0.38) | WEE1JAK3FGFR1PDGFRBSRC | |
| SCHEMBL15787977 | 0.76 | TNK2 (0.42) | JAK3PAK4PKN1TNK2 | |
| SCHEMBL14682082 | 0.75 | JAK3 (0.47) | JAK3FGFR1SRCPAK4PKN1 | |
| SCHEMBL15041278 | 0.74 | JAK3 (0.44) | WEE1JAK3PAK4PKN1TNK2 | |
| SCHEMBL15785220 | 0.74 | PAK4 (0.51) | WEE1JAK3PAK4PKN1TNK2 | |
| SCHEMBL15787978 | 0.73 | JAK3 (0.50) | JAK3SRCPAK4PKN1TNK2 | |
| SCHEMBL15035128 | 0.72 | PAK4 (0.45) | WEE1JAK3PAK4PKN1TNK2 | |
| SCHEMBL13553903 | 0.72 | TNK2 (0.44) | JAK3SRCPAK4PKN1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | WEE1 850/4885JAK3 783/4885FGFR1 2256/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885JAK3 1901/4885FGFR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.